Payment overview · 2025
General Payments
$588.98
36 reported records · 15 companies
Healthcare provider profile · identity verified
Edward Nelson Barr, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MINERVA, OH · NPI 1619978723
Verified facts
What the public records show
CMS Open Payments records show Edward Nelson Barr, M.D. received $588.98 in general payments during 2025 across 36 reported records.
GlaxoSmithKline, LLC. accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 342 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 342 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 500 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $88.96 | 15.1% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.68 | 10.5% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $59.43 | 10.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.27 | 8.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $45.75 | 7.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.68 | 6.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.55 | 5.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.15 | 5.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $31.49 | 5.3% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $31.01 | 5.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.36 | 5.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.39 | 4.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.82 | 3.9% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $21.57 | 3.7% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $13.87 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $588.98 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $88.96 | 6 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $59.43 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.27 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $45.75 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.68 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.68 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.68 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $34.75 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.15 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $32.22 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $31.49 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $31.01 | 2 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $31.01 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $31.01 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $31.01 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.36 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.39 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 500 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 342 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
342 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
78 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
342 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
56 | 56 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
500 | 55 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 675 | 140 |
| Levothyroxine Sodium | Levothyroxine Sodium | 566 | 89 |
| Eliquis | Apixaban | 500 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 467 | 96 |
| Lisinopril | Lisinopril | 426 | 98 |
| Furosemide | Furosemide | 399 | 52 |
| Jardiance | Empagliflozin | 342 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 323 | 64 |
| Gabapentin | Gabapentin | 318 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 312 | 68 |
| Omeprazole | Omeprazole | 289 | 75 |
| Trazodone Hcl | Trazodone Hcl | 267 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 234 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 234 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 227 | 44 |
| Divalproex Sodium | Divalproex Sodium | 222 | 26 |
| Losartan Potassium | Losartan Potassium | 215 | 50 |
| Metformin Hcl | Metformin Hcl | 192 | 41 |
| Sertraline Hcl | Sertraline Hcl | 172 | 30 |
| Baclofen | Baclofen | 171 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 44 |
| Mirtazapine | Mirtazapine | 161 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 157 | 20 |
| Lorazepam | Lorazepam | 155 | 30 |
| Alprazolam | Alprazolam | 154 | 23 |
| Simvastatin | Simvastatin | 143 | 32 |
| Metformin Hcl Er | Metformin Hcl | 140 | 35 |
| Paroxetine Hcl | Paroxetine Hcl | 138 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 58 |
| Prednisone | Prednisone | 129 | 47 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 123 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 119 | 25 |
| Buspirone Hcl | Buspirone Hcl | 117 | 21 |
| Memantine Hcl | Memantine Hcl | 116 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 29 |
| Potassium Chloride | Potassium Chloride | 112 | 27 |
| Ondansetron Odt | Ondansetron | 111 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 33 |
| Tramadol Hcl | Tramadol Hcl | 107 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 102 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 14 |
| Allopurinol | Allopurinol | 98 | 17 |
| Clonazepam | Clonazepam | 98 | suppressed |
| Famotidine | Famotidine | 97 | 21 |
| Warfarin Sodium | Warfarin Sodium | 96 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 14 |
| Donepezil Hcl | Donepezil Hcl | 86 | 15 |
| Carvedilol | Carvedilol | 85 | 18 |
| Finasteride | Finasteride | 85 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 17 |
| Montelukast Sodium | Montelukast Sodium | 76 | 15 |
| Glipizide Er | Glipizide | 72 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 19 |
| Cephalexin | Cephalexin | 67 | 36 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 66 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 66 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 65 | 13 |
| Meloxicam | Meloxicam | 65 | 13 |
| Celecoxib | Celecoxib | 64 | 18 |
| Fetzima | Levomilnacipran Hcl | 64 | suppressed |
| Lamotrigine | Lamotrigine | 64 | suppressed |
| Xarelto | Rivaroxaban | 64 | suppressed |
| Lansoprazole | Lansoprazole | 62 | suppressed |
| Cimetidine | Cimetidine | 61 | suppressed |
| Atenolol | Atenolol | 58 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 58 | suppressed |
| Levetiracetam | Levetiracetam | 58 | 11 |
| Rivastigmine | Rivastigmine Tartrate | 57 | suppressed |
| Spironolactone | Spironolactone | 57 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 34 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 56 | 56 |
| Risperidone | Risperidone | 52 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 11 |
| Alendronate Sodium | Alendronate Sodium | 51 | suppressed |
| Chlorthalidone | Chlorthalidone | 51 | suppressed |
| Bumetanide | Bumetanide | 50 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 49 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 49 | 21 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 49 | 48 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 27 |
| Fentanyl | Fentanyl | 47 | suppressed |
| Glimepiride | Glimepiride | 47 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 44 | suppressed |
| Amoxicillin | Amoxicillin | 44 | 28 |
| Myrbetriq | Mirabegron | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Sucralfate | Sucralfate | 41 | suppressed |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 35 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | 13 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Paliperidone Er | Paliperidone | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 17 |
| Carbamazepine | Carbamazepine | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Rivastigmine | Rivastigmine | 32 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Phenobarbital | Phenobarbital | 30 | suppressed |
| Austedo | Deutetrabenazine | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 20 |
| Ertapenem | Ertapenem Sodium | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 18 |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Movantik | Naloxegol Oxalate | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Glatopa | Glatiramer Acetate | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 12 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Metolazone | Metolazone | 23 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Budesonide | Budesonide | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 16 |
| Naltrexone Hcl | Naltrexone Hcl | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Cyclosporine | Cyclosporine | 19 | suppressed |
| Mirabegron Er | Mirabegron | 19 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Olanzapine | Olanzapine | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | 12 |
| Calcitriol | Calcitriol | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Zafirlukast | Zafirlukast | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $588.98 · 36 records | GlaxoSmithKline, LLC. | BREZTRI, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, ENFLONSIA, GARDASIL 9, INGREZZA, INSPIRE, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ohtuvayre, PROQUAD, Quviviq, ROTATEQ, TRELEGY ELLIPTA, VAXNEUVANCE, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error